Fayetteville, AR - Cellia Science, a point-of-care hematology company, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) for $275,985.
The grant will be used to conduct research and development work on their microfluidic cartridge. This cartridge is designed to enable rapid, accurate blood cell analysis in any setting from only a drop of blood.
“We are thrilled to have the support of NHLBI for the development of our hematology analysis system,” said Kelly Mabry, CEO and Co-Founder of Cellia Science. “Our approach is unique because rather than miniaturizing or automating existing technologies, we are implementing our new, proprietary deep-UV imaging technology coupled with deep learning algorithms to analyze the cells, which results in high accuracy for the critical parameters required to manage oncology patient care. We are highly motivated to get this technology into the clinic, where we hope to reduce delays in treatment administration and improve patient care.”
About Cellia Science
Cellia Science was formed in 2021 to develop and commercialize blood cell analyzers that provide rapid, actionable blood cell counts at the point of care. The foundation of Cellia’s blood cell analyzer is based on label-free deep-UV imaging technology exclusively licensed from the Georgia Institute of Technology. The Company’s lead device will provide blood cell counts for chemotherapy patients at risk of neutropenia and thrombocytopenia. Follow-on versions of the technology will be applied to additional diseases with significant unmet needs. To learn more, visit celliasci.com
About The National Institutes of Health
NIH is the steward of medical and behavioral research for the Nation. Its mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.